Navigation Links
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
Date:6/8/2009

current analysis confirmed that CPX-351 maintained the fixed 5:1 molar ratio of cytarabine:daunorubicin for prolonged periods of time (24 hours and longer) after administration. It also showed that while the bioavailability of the encapsulated drugs was similar to that expected with conventional administration, CPX-351 produced prolonged half-lives for both agents and accumulation of the drugs over the three dose induction course (infusions on Days 1, 3, 5). These results suggest that effective drug exposure could be extended beyond that produced by conventional administration of this drug combination. The further observation that circulating liposomal drug could be detected in the plasma up to Day 12, while remaining bioavailable, led the investigators to conclude that leukemia cells could be exposed to cytotoxic drug levels throughout the first two weeks of induction treatment.

In a separate poster presentation, researchers described the results of a preclinical study comparing the sensitivity of various blood cell types to CPX-351 and evaluating the uptake of CPX-351 by human leukemia cells both in vitro and in vivo (mouse xenograft models).(2) They reported that CPX-351 ablated leukemic cells but permitted the regrowth of normal bone marrow cells within 42 days of treatment in a Rag2-M mouse xenograft model. These mice remained leukemia-free for up to 70 days (saline-treated controls all died by Day 42). In several additional experiments, investigators confirmed the presence of intact CPX-351 liposomes inside the leukemia cells, allowing the release of the synergistic 5:1 molar ratio of the active agents intracellularly, and demonstrated that CPX-351 is taken up in higher levels by leukemic cells in the bone marrow than by normal bone marrow cells. They concluded that the preferential uptake of CPX-351 by leukemia cells may contribute to its enhanced efficacy and improved therapeutic index.

About Celator P
'/>"/>

SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
2. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
3. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
4. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
5. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
6. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... N.J. , Aug. 27, 2014  A ... potential to help physicians better identify early-stage disease, ... and disability, according to a new study in ... Quest Diagnostics (NYSE: DGX ) and ... the 14-3-3eta protein outperformed conventional antibody-serum testing, including ...
(Date:8/27/2014)... -- Research and Markets has announced the ... Paper Industry Report 2014" report to their offering. ... Paper Industry Report 2014 is a professional and in-depth ... for pulp & paper industry. The report ... classifications, applications and industry chain structure. The enzyme for ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Ala., Jan. 8 BioCryst Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and Dr. William P. Sheridan, Chief Medical ... J.P. Morgan 27th Annual Healthcare Conference on Thursday, January 15, ... be held January 12-15, 2009 in San Francisco.A link to ...
... DNDN ) today announced that management will present ... Francisco on Thursday, January 15, 2009 at 11:00 a.m. PT. ... be accessible through the Investor Relations section of the Dendreon ... to the live webcast, it will be archived on the ...
... Medical, Inc., the global leader in devices for clot ... has completed a $15 million round of financing. ... New Enterprise Associates, Inc. (NEA) and includes other existing ... the last several months made the opportunity to participate ...
Cached Biology Technology:BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 2BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference 3Concentric Medical Closes on $15 Million Financing 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... growing number of studies have shown that ... pathogenesis of Parkinson,s disease. Previous studies from ... University in China have shown that baicalin ... reduced divalent metal transporter 1 expression, and ... nigra of rotenone-induced Parkinson,s disease rats. However, ...
(Date:8/27/2014)... the Happy Camp Complex of fires had consumed 24,939 ... had consumed 35,530 as of eight hours ago. ... Camp Ranger District of the Klamath National Forest when ... 2014. All but three of those fires are now ... contained fires and their size at containment: Delta, 150 ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... 2010) The New York Stem Cell Foundation (NYSCF) today ... postdoctoral scientists join 15 accomplished stem cell researchers from leading ... NYSCF has awarded 23 fellowships to date. ... most competitive postdoctoral fellowship programs in the world, has so ...
... year The International Institute for Species Exploration at Arizona State ... previous calendar year. The list for 2009 was published to ... birth of Carl Linnaeus. It contains only two new plant ... Botanical Journal of the Linnean Society . ...
... SPRING HARBOR, N.Y. (Tues., June 1, 2010) -- ... frequently used techniques in RNA analysis. Electrophoresis is ... quality assessment. Gels are involved in a wide ... and analyzing processing reactions. The two most common ...
Cached Biology News:NYSCF awards fellowships to 8 innovative stem cell scientists 2NYSCF awards fellowships to 8 innovative stem cell scientists 3Rare carnivorous plant on top 10 list of newly discovered species 2Electrophoresis of RNA, avian imaging featured in June's Cold Spring Harbor Protocols 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
UV-NIR light source for USB2000, HR4000, HR2000+...
Biology Products: